Dongwoo Hahn

Dongwoo Hahn

Auto-generated profile, based on publicly available information

Dongwoo Hahn

Department of Integrative Biology and Physiology, University of Minnesota Medical School

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AMAshley Martin
Ashley Martin
BTBrian R. Thompson
Brian R. Thompson
DHDongwoo Hahn
Dongwoo Hahn
AAAddeli Bez Batti Angulski
Addeli Bez Batti Angulski
NHNora Hosny
Nora Hosny
JMJoseph M. Metzger
Joseph M. Metzger
The cardiac sarcomere is a triumph of biological evolution wherein myriad contractile and regulatory proteins assemble into a quasi-crystalline lattice to serve as the central point upon which cardiac muscle contraction occurs. This review focuses on the many signaling components and mechanisms of regulation that impact cardiac sarcomere function. We highlight the roles of the thick and thin filament, both as necessary structural and regulatory building blocks of the sarcomere as well as targets of functionally impactful modifications. Currently, a new focus emerging in the field is inter-myofilament signaling, and we discuss here the important mediators of this mechanism, including myosin-binding protein C and titin. As the understanding of sarcomere signaling advances, so do the methods with which it is studied. This is reviewed here through discussion of recent live muscle systems in which the sarcomere can be studied under intact, physiologically relevant conditions.

1 January 2022 in Journal of Applied Physiology
Verified
Journal Article
Closed access
PDF file
RKRachel C. Kelley
Rachel C. Kelley
LBLauren Betancourt
Lauren Betancourt
ANAndrea M. Noriega
Andrea M. Noriega
SBSuzanne C. Brinson
Suzanne C. Brinson
NCNuria Curbelo-Bermudez
Nuria Curbelo-Bermudez
Leonardo FerreiraLeonardo Ferreira
Leonardo Ferreira
Heart failure with preserved ejection fraction (HFpEF) accounts for ∼50% of all patients with heart failure and frequently affects postmenopausal women. The HFpEF condition is phenotype-specific, with skeletal myopathy that is crucial for disease development and progression. However, most of the current preclinical models of HFpEF have not addressed the postmenopausal phenotype. We sought to advance a rodent model of postmenopausal HFpEF and examine skeletal muscle abnormalities therein. Female, ovariectomized, spontaneously hypertensive rats (SHRs) were fed a high-fat, high-sucrose diet to induce HFpEF. Controls were female sham-operated Wistar-Kyoto rats on a lean diet. In a complementary, longer-term cohort, controls were female sham-operated SHRs on a lean diet to evaluate the effect of strain difference in the model. Our model developed key features of HFpEF that included increased body weight, glucose intolerance, hypertension, cardiac hypertrophy, diastolic dysfunction, exercise intolerance, and elevated plasma cytokines. In limb skeletal muscle, HFpEF decreased specific force by 15%–30% (P < 0.05) and maximal mitochondrial respiration by 40%–55% (P < 0.05), increased oxidized glutathione by approximately twofold (P < 0.05), and tended to increase mitochondrial H2O2 emission (P = 0.10). Muscle fiber cross-sectional area, markers of mitochondrial content, and indices of capillarity were not different between control and HFpEF in our short-term cohort. Overall, our preclinical model of postmenopausal HFpEF recapitulates several key features of the disease. This new model reveals contractile and mitochondrial dysfunction and redox imbalance that are potential contributors to abnormal metabolism, exercise intolerance, and diminished quality of life in patients with postmenopausal HFpEF. NEW & NOTEWORTHY Heart failure with preserved ejection fraction (HFpEF) is a condition with phenotype-specific features highly prevalent in postmenopausal women and skeletal myopathy contributing to disease development and progression. We advanced a rat model of postmenopausal HFpEF with key cardiovascular and systemic features of the disease. Our study shows that the skeletal myopathy of postmenopausal HFpEF includes loss of limb muscle-specific force independent of atrophy, mitochondrial dysfunction, and oxidized shift in redox balance.

13 October 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
HCHouda Cohen
Houda Cohen
AAAddeli Bez Batti Angulski
Addeli Bez Batti Angulski
JQJoseph D. Quick
Joseph D. Quick
TKTaylor S. Kuebler
Taylor S. Kuebler
BTBrian R. Thompson
Brian R. Thompson
JMJoseph M. Metzger
Joseph M. Metzger
Duchenne muscular dystrophy (DMD) is a fatal genetic disease of progressive muscle deterioration with no cure. DMD treatment requires a body-wide approach to target all diseased striated muscles: limb, respiratory, and heart. To address this, we focus studies on blocking the onset of muscle membrane instability, the primary defect in DMD, as a promising yet unmet druggable target. Here, data show the remarkable potency of a synthetic poly(ethylene oxide)/poly(propylene oxide) side chain–based bottlebrush block copolymer, ~150,000 times more potent than linear polymers, to rapidly restore contractile function to DMD skeletal muscle fibers in vitro. Strikingly, upon bottlebrush polymer delivery to DMD animals, results show highly efficacious prevention of the onset of skeletal and diaphragm muscle damage and the blocking of stress-induced cardiac injury and death in vivo. These data suggest bottlebrush polymers as a potent stand-alone muscle membrane-stabilizing therapeutic for DMD. Given DMD’s early childhood onset, together with newborn screening for DMD, bottlebrush macromolecules could be envisioned as an early therapy to preserve and protect viable muscle and potentially for other acquired or inherited diseases involving membrane damage.

1 April 2019 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
RKRavi A Kumar
Ravi A Kumar
DHDongwoo Hahn
Dongwoo Hahn
RKRachel Kelley
Rachel Kelley
Leonardo FerreiraLeonardo Ferreira
Leonardo Ferreira
Acute dietary nitrate supplementation in humans (within 2 hours) increases limb muscle peak power. In old mice, chronic (14 days) dietary nitrate supplementation increases diaphragm peak power. However, mechanisms of dietary nitrate effects on contractile mechanics are not fully understood. It is unclear whether nitrate ions directly or products downstream of the nitrate‐nitrite‐nitric oxide (NO) reductive pathway are responsible for changes in muscle contractile function. Increases in power likely involve post‐translational modification of myofibrillar proteins – phosphorylation being an established effect of NO signaling. We determined the phosphorylation status of myofibrillar proteins from diaphragms of 24 month old mice supplemented with nitrate (n = 8) or control (n = 6) and found no difference for myosin regulatory light chain, myosin binding protein c, tropomyosin, desmin or troponin I. Regulatory light chain phosphorylation signal normalized to total protein was 1.696 ± 0.139 and 1.699 ± 0.105 for control and nitrate‐supplemented animals, respectively. To examine a direct effect of nitrate on muscle cells, we exposed isolated diaphragm bundles from young mice in vitro to increasing concentrations of NaNO 3 . In vitro NaNO 3 (15 min) had no effect on diaphragm peak power or isometric force (P > 0.05). Specifically, power (% control) was −1.06 ± 0.20 (0.5 mM), −1.73 ± 0.79 (1 mM), −2.64 ± 2.14 (2 mM), and −2.40 ± 2.40 (4 mM). Overall, our study shows that the increase in diaphragm power of aged mice elicited by chronic dietary nitrate supplementation does not involve changes in phosphorylation of key sarcomeric proteins that regulate contractile function. Moreover, our data from in vitro experiments suggest no direct effect of nitrate ions on mammalian skeletal muscle contractile function. Instead, dietary nitrate effects on muscle function appear to require whole‐body physiological mechanisms and actions of molecules downstream of nitrate. This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .